Paroxetine EP Impurity E
 
		Product Description
CAT No.
				
									ALN-P012006								
				CAS No.
				
									72473-26-8								
				Mol. F.
				
									C19H20FNO3								
				Mol. Wt.
				
									329.4								
				Stock
				
									Please Inquire								
				
										
							
										Product Overview
						
											
										
							
										Technical Data
						
											
										
							
										Reference
						
											
										
							
										RFQ
						
									
							
							
							Product Overview
			
						
									Chemical Name : (3RS,4RS)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine								
				
									Smiles : FC1=CC=C([C@@]2([H])[C@](COC(C=C3)=CC4=C3OCO4)([H])CNCC2)C=C1								
				
									Synonym : cis-paroxetine ; Paroxetine USP Related Compound D								
				
							
							
							Technical Data
			
						
							
							
							Reference
			
						Development, validation and transfer into a factory environment of a liquid chromatography tandem mass spectrometry assay for the highly neurotoxic impurity FMTP (4-(4-fluorophenyl)-1-methyl-1,2,3,6-tetrahydropyridine) in paroxetine active pharmaceutical ingredient (API)
									Phil J.Borman, Marion J.Chatfield, Elizabeth L.Crowley, ChristineEckers, David P.Elder, Scott W.Francey, Alice M.-F.Laures, Jean-ClaudeWolffnJournal of Pharmaceutical and Biomedical Analysis Volume 48, Issue 4, 1 December 2008, Pages 1082-1089								
				An Investigation into the Dehydration Behavior of Paroxetine HCl Form I Using a Combination of Thermal and Diffraction Methods: The Identification and Characterization of a New Anhydrous Form
									M. Fátima Pina, Min Zhao, João F. Pinto, João J. Sousa, Christopher S. Frampton, Victor Diaz, Osama Suleiman, László Fábián, and Duncan Q. M. Craig – Cryst. Growth Des. 2014, 14, 8, 3774–3782 								
				Determination of residual solvents in paroxetine by headspace gas chromatography
									abdul rahaman sk, padmavathi sakinala, khaleel n, harekrishna roy – Asian J Pharm Clin Res, Vol 12, Issue 6, 2019, 150-155 								
				
							
							
							RFQ
			
						
 
                             
                             
                             
                             
                            